ClinicalTrials.gg
Not yet recruitingNCT07623044DAIMASUpdated Jun 3, 2026

Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD

A Phase 2 interventional study of Daidzein in Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by Eastern Hepatobiliary Surgery Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Eastern Hepatobiliary Surgery Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This clinical trial aims to learn whether daidzein can improve liver tissue changes in adults with metabolic dysfunction-associated steatotic liver disease, also called MASLD. MASLD is a liver condition linked to extra fat in the liver and metabolic problems such as obesity, diabetes, abnormal blood lipids, or high blood pressure.

Daidzein is a natural compound found in soy. Earlier laboratory studies suggest that daidzein may help protect the liver. This study will test whether taking daidzein for a short time before surgery can improve liver tissue findings in people with MASLD.

The main questions this study aims to answer are:

Does short-term daidzein treatment improve liver tissue injury in people with MASLD? Is daidzein safe and well tolerated before surgery? Are changes in blood or urine equol levels related to the effects of daidzein? Equol is a substance made by gut bacteria after some people take daidzein.

Researchers will compare people who take daidzein before surgery with people who receive standard care without daidzein.

Participants will:

Be adults with MASLD who are scheduled for elective gallbladder surgery or another benign biliary surgery.

Be randomly assigned to take daidzein or to receive standard care without daidzein.

Take daidzein by mouth for 28 days before surgery if assigned to the daidzein group.

Avoid soy foods during the study period. Provide blood and urine samples. Have a small liver tissue sample collected during surgery. Be followed for safety and recovery after surgery.

The liver tissue sample will be used to check liver fat, inflammation, and liver cell injury. Researchers will also study markers related to liver injury, immune activity, and how the body responds to daidzein.

Read the detailed description

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is one of the most common chronic liver diseases. It is closely associated with obesity, type 2 diabetes, dyslipidemia, hypertension, and other cardiometabolic risk factors. MASLD is diagnosed when hepatic steatosis is present together with at least one cardiometabolic risk factor. Its disease spectrum ranges from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Because of its high prevalence and potential for disease progression, MASLD has become an important public health problem.

Current treatment strategies for MASLD mainly include weight reduction, dietary control, physical activity, and management of metabolic abnormalities. However, these approaches may be difficult to standardize and maintain over time, and treatment responses vary among individuals. There remains a need for safe, practical, and mechanism-based interventions that may improve liver injury and disease activity in MASLD.

MASLD is not only a metabolic liver disease but also an immunometabolic disease. Its development and progression involve hepatic lipid accumulation, oxidative stress, hepatocellular injury, ferroptosis-related biological changes, and immune-inflammatory responses. However, direct evidence from human liver tissue remains limited. In particular, it is unclear whether a short-term, mechanism-oriented intervention can induce measurable changes in liver histology, ferroptosis-related markers, and intrahepatic immune-inflammatory features in patients with MASLD.

Daidzein is an important bioactive component of soy isoflavones. It has been reported to have metabolic regulatory, antioxidant, and anti-inflammatory properties. Previous experimental studies by the investigators suggest that daidzein can improve metabolic dysfunction and reduce liver injury in MASLD models. These studies also suggest that the beneficial effects of daidzein may depend, at least in part, on gut microbiota-mediated metabolic conversion.

The investigators' preclinical work combining metagenomic and metabolomic analyses identified equol as a key gut microbiota-derived metabolite that increases after daidzein intervention. Mechanistic findings suggest that the daidzein-equol axis may improve MASLD-related liver injury by coordinating hepatocyte protection and restraint of immune-inflammatory responses. These findings provide a scientific basis for evaluating daidzein in a clinical translational setting.

Several important questions remain unanswered. First, the effects of daidzein in humans may be influenced by the metabolic capacity of the gut microbiota. Not all individuals can efficiently convert daidzein into equol. Therefore, the response to daidzein may vary between equol producers and non-producers. Second, whether equol-producing capacity is associated with the magnitude of response to daidzein has not been prospectively evaluated in patients with MASLD. Third, although preclinical studies suggest that the daidzein-equol axis may regulate ferroptosis and immune-inflammatory responses, it remains unknown whether short-term daidzein intervention can produce detectable changes in human liver tissue.

This study is designed to address these questions using a perioperative window-of-opportunity approach. Adult patients with MASLD who are scheduled to undergo elective laparoscopic cholecystectomy or other benign biliary surgery will be enrolled. This clinical setting provides a feasible opportunity for short-term preoperative intervention without delaying or replacing standard surgical care. It also allows intraoperative collection of a small liver tissue sample for direct histological and biomarker assessment.

This is a prospective, open-label, randomized controlled study. Eligible participants will be randomly assigned in a one-to-one ratio to a daidzein intervention group or a control group. Participants in the daidzein group will receive oral daidzein capsules before surgery. Participants in the control group will receive standard perioperative care without daidzein intervention. Both groups will undergo their planned surgical procedure according to routine clinical practice.

The overall objective of the study is to evaluate whether short-term perioperative daidzein intervention can improve liver histological changes in patients with MASLD and to explore its biological effects on ferroptosis-related markers, intrahepatic immune-inflammatory features, and equol-related metabolic heterogeneity. The primary scientific focus is the difference in liver histological activity between the daidzein group and the control group based on intraoperative liver tissue assessment.

Liver histological activity will be evaluated using the NAFLD Activity Score system. Although MASLD terminology is used in this study, the NAFLD Activity Score remains a widely used histological scoring system for assessing steatosis, lobular inflammation, and hepatocellular ballooning. These components will be used to assess liver tissue activity and injury.

The study will also assess ferroptosis-related markers in liver tissue. Core markers such as GPX4 and ACSL4 will be evaluated by methods such as immunohistochemistry or immunofluorescence. These analyses are intended to explore whether daidzein intervention is associated with changes in ferroptosis-related biological features in human MASLD liver tissue.

Intrahepatic immune-inflammatory features will also be explored. The study will evaluate CD8-positive T-cell infiltration and related inflammatory features in liver tissue. These assessments are intended to examine whether daidzein may influence the immune-inflammatory microenvironment in MASLD.

Blood and urine samples will be collected to measure equol levels and selected biochemical and metabolic indicators. Equol measurements will be used to explore whether the ability to produce equol is associated with the response to daidzein. This exploratory analysis may help identify biological factors that contribute to individual differences in response to daidzein intervention.

The study will also assess clinical laboratory indicators, including liver enzymes and metabolic parameters. These data will be used together with liver tissue findings to provide a more comprehensive assessment of the biological effects of daidzein. Safety and tolerability will be monitored throughout the study, including adverse events, perioperative complications, and postoperative recovery.

The planned sample size is forty-four participants, with twenty-two participants in each group. This sample size is intended to support an exploratory, early-phase mechanistic clinical study. The study is not designed to provide definitive evidence of long-term clinical efficacy. Instead, it is intended to provide early human tissue-level evidence on whether short-term daidzein intervention can produce measurable histological and biological changes in MASLD.

The observation period will extend from enrollment to thirty days after surgery. Data collection will include baseline clinical information, relevant medical history, imaging information, medication use, intervention adherence, adverse events, intraoperative liver tissue findings, blood and urine test results, perioperative complications, and short-term postoperative recovery.

Although the study is open-label for participants and clinical investigators, outcome assessment will include measures to reduce bias. Liver tissue samples will be coded and de-identified whenever feasible. Histological evaluation will be performed by independent pathologists or trained evaluators who are not involved in treatment allocation or intervention management. Immunohistochemistry, immunofluorescence, and related molecular assessments will also be performed under blinded or independent evaluation conditions whenever possible.

Data will be collected using case report forms and entered into a study database. Each participant will be assigned a unique study identification code. Personal information will be protected through de-identification and restricted data access. Data quality procedures will include double checking of key data, review of missing values, range checks, consistency checks, and source data verification when needed. Corrections to study data will follow predefined procedures to ensure accuracy, completeness, and traceability.

The statistical analysis will be conducted according to predefined analysis principles. Continuous variables will be summarized using means and standard deviations or medians and interquartile ranges, depending on data distribution. Categorical variables will be summarized using counts and percentages. Between-group comparisons will be performed using appropriate statistical tests based on the type and distribution of the data. Safety analyses will summarize adverse events, serious adverse events, perioperative complications, and tolerability. Exploratory analyses will evaluate whether equol-producing capacity is associated with differences in liver histology, biomarker changes, or other biological responses to daidzein.

This study is expected to provide early clinical and translational evidence for the potential role of daidzein in MASLD. By using intraoperative liver tissue assessment, the study may help determine whether short-term daidzein intervention can induce measurable improvements in liver histological activity and related biological abnormalities. The findings may also provide preliminary evidence for the role of gut microbiota-derived equol in shaping individual responses to daidzein.

02

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Keywords

  • Metabolic dysfunction-associated steatotic liver disease
  • Daidzein
  • Ferroptosis
  • Randomized controlled trial
  • Soy isoflavone
03

In context

Lead sponsor

Eastern Hepatobiliary Surgery Hospital is the lead sponsor of 69 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 70 years.
  • Male or female participants.
  • Scheduled to undergo elective laparoscopic cholecystectomy or other benign biliary surgery for benign biliary disease.
  • Diagnosis of metabolic dysfunction-associated steatotic liver disease based on hepatic steatosis shown by liver or imaging, including controlled attenuation parameter, ultrasound, or magnetic resonance imaging, together with at least one cardiometabolic risk factor.
  • Expected preoperative window of at least 28 days before surgery.
  • Able and willing to provide written .
  • Willing to provide blood samples, urine samples, and intraoperative liver tissue samples.
  • Able and willing to avoid soy-containing foods during the study period, including soybeans, edamame, black soybeans, soy milk, tofu, dried tofu, tofu skin, yuba, tofu pudding, natto, miso, fermented soybeans, tempeh, and other traditional or fermented soy products.

Exclusion criteria

Exclusion Criteria:

  • Viral hepatitis, liver disease, drug-induced liver injury, Wilson disease, or other clearly defined chronic liver diseases.
  • Significant alcohol consumption, defined as more than 140 g per week for women or more than 210 g per week for men.
  • Liver cirrhosis, decompensated liver disease, or hepatobiliary .
  • Use of antibiotics, probiotics, soy isoflavone-containing products, or hormone-like dietary supplements within 4 weeks before enrollment.
  • Treatment within 3 months before enrollment that may substantially affect body weight or the severity of fatty liver disease.
  • Known allergy to soy products, daidzein, or isoflavones.
  • Pregnancy or breastfeeding.
  • Any condition that, in the opinion of the investigator, makes the participant unsuitable for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Daidzein Group

    Participants assigned to this arm will receive oral daidzein capsules before surgery in addition to standard perioperative care. Daidzein will be administered for 28 consecutive days before the planned elective laparoscopic cholecystectomy or other benign biliary surgery. Participants will undergo surgery according to routine clinical practice, and a small liver tissue sample will be collected intraoperatively for histological and biomarker assessment.

    Drug: Daidzein

  • No intervention
    Control Group

    Participants assigned to this arm will receive standard perioperative care without daidzein intervention. They will undergo the planned elective laparoscopic cholecystectomy or other benign biliary surgery according to routine clinical practice. A small liver tissue sample will be collected intraoperatively for histological and biomarker assessment. 中文对应

Interventions

  • Daidzein will be administered orally as capsules. Participants assigned to the daidzein group will take 50 mg per dose, three times daily, for a total daily dose of 150 mg. Treatment will continue for 28 consecutive days before surgery and until the day before surgery. Daidzein will be given in addition to standard perioperative care.

06

What researchers measure

Primary outcomes

  1. NAFLD Activity Score in Intraoperative Liver Tissue

    The NAFLD Activity Score will be assessed using liver tissue collected during surgery. The score includes steatosis, lobular inflammation, and hepatocellular ballooning. The total score ranges from 0 to 8, with higher scores indicating greater histological activity of MASLD-related liver injury.

    Time frame: At the time of surgery

Secondary outcomes

  1. Steatosis Grade in Intraoperative Liver Tissue

    Hepatic steatosis will be graded using intraoperative liver tissue according to the steatosis component of the NAFLD Activity Score. The score ranges from 0 to 3, with higher scores indicating more severe hepatic steatosis.

    Time frame: At the time of surgery

  2. Lobular Inflammation Score in Intraoperative Liver Tissue

    Lobular inflammation will be assessed using intraoperative liver tissue according to the lobular inflammation component of the NAFLD Activity Score. The score ranges from 0 to 3, with higher scores indicating more severe lobular inflammation.

    Time frame: At the time of surgery

  3. Hepatocellular Ballooning Score in Intraoperative Liver Tissue

    Hepatocellular ballooning will be assessed using intraoperative liver tissue according to the ballooning component of the NAFLD Activity Score. The score ranges from 0 to 2, with higher scores indicating more severe hepatocellular ballooning.

    Time frame: At the time of surgery

  4. Ferroptosis-related Marker Expression in Intraoperative Liver Tissue

    Ferroptosis-related markers, including GPX4 and ACSL4, will be assessed in liver tissue collected during surgery using immunohistochemistry, immunofluorescence, or other predefined protein detection methods. Quantitative or semi-quantitative expression levels will be compared between study groups.

    Time frame: At the time of surgery

  5. CD8-positive T-cell Infiltration in Intraoperative Liver Tissue

    CD8-positive T-cell infiltration will be assessed in liver tissue collected during surgery using immunohistochemistry, immunofluorescence, or other predefined tissue-based methods. The density or proportion of CD8-positive T cells will be compared between study groups.

    Time frame: At the time of surgery

  6. Serum Liver Enzyme Levels

    Serum liver enzyme levels, including alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase, will be measured using routine clinical laboratory tests. Changes from baseline to the preoperative assessment will be compared between study groups.

    Time frame: Baseline and within 1 to 3 days before surgery

  7. Change From Baseline in Triglyceride Level

    Serum triglyceride level will be measured using routine clinical laboratory tests. The change from baseline to the preoperative assessment will be compared between study groups.

    Time frame: Baseline and within 1 to 3 days before surgery

  8. Change From Baseline in Low-density Lipoprotein Cholesterol Level

    Serum low-density lipoprotein cholesterol level will be measured using routine clinical laboratory tests. The change from baseline to the preoperative assessment will be compared between study groups

    Time frame: Baseline and within 1 to 3 days before surgery

  9. Blood and Urine Equol Concentrations

    Blood and urine equol concentrations will be measured using predefined laboratory methods. Equol levels will be used to explore daidzein metabolism and potential differences in response between equol producers and non-producers.

    Time frame: Baseline and within 1 to 3 days before surgery

  10. Adverse Events

    Adverse events will be recorded throughout the study. Events will be summarized by frequency, severity, seriousness, and relationship to the study intervention.

    Time frame: From enrollment through 30 days after surgery

  11. Perioperative Complications

    Perioperative complications will be recorded during hospitalization and postoperative follow-up. Complications will be summarized by frequency, type, and severity.

    Time frame: From surgery through 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in the final publication may be shared. Shared data may include baseline characteristics, intervention adherence, liver histopathology scores, selected laboratory test results, equol measurements, biomarker data, and safety outcomes. Data that could directly identify participants or compromise privacy will not be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will become available beginning 6 months after publication of the main study results and will be available for 3 years.

Access criteria: Data will be shared with qualified researchers who submit a scientifically sound research proposal. Requests will be reviewed by the principal investigator and the study team. Data sharing will require approval of the proposed analysis, a signed data use agreement, and compliance with applicable ethical and privacy requirements. Data may be used for academic, non-commercial research related to MASLD, daidzein, liver histopathology, metabolic biomarkers, or related translational analyses.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Jul 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
Jun 3, 2026
StartEst.
May 21, 2026
Primary completionEst.
Jul 10, 2026
CompletionEst.
Aug 10, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623044
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Responsible party
Shen Feng (Principal Investigator, Eastern Hepatobiliary Surgery Hospital) — Principal investigator
First posted
Jun 3, 2026
Start date
May 21, 2026 (estimated)
Primary completion
Jul 10, 2026 (estimated)
Completion
Aug 10, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Feng Shen, MD、PhD
Contact
shenfengdfgd@163.com
+86-21-81875005
Feng Shen, MD, PhD
principal investigator · Clinical Research Institute, Eastern Hepatobiliary Surgery Hospital and National Centre for Liver Cancer, Naval Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daidzein

Start the discussion